Genelux Corp is a clinical-stage biopharmaceutical company... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
GNLX is expected to report earnings to fall 12.00% to -21 cents per share on May 08
Q1'25
Est.
$-0.22
Q4'24
Est.
$-0.25
Q3'24
Beat
by $0.06
Q2'24
Beat
by $0.02
Q1'24
Missed
by $0.06
The last earnings report on March 28 showed earnings per share of -25 cents, meeting the estimate of -25 cents. With 235.51K shares outstanding, the current market capitalization sits at 95.51M.